Midmichigan Medical Ctr
- Type
- Teaching hospital
- Where
- MIDLAND, MI
- Medicare CCN
- 230222
- Received
- $240,155 in 106 records, 2020 ($58,786 general, $181,369 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 12 | $58,786 |
| 2020 | Research payment | 94 | $181,369 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Abbott Laboratories | 28 | $66,799 | 2020 |
| PRINCIPIA BIOPHARMA INC. | 8 | $43,469 | 2020 |
| Smith+Nephew, Inc. | 1 | $32,733 | 2020 |
| CSL Behring | 19 | $26,541 | 2020 |
| Boston Scientific Corporation | 11 | $25,442 | 2020 |
| Amgen Inc. | 7 | $22,213 | 2020 |
| Medtronic MiniMed, Inc. | 4 | $12,262 | 2020 |
| Daiichi Sankyo Inc. | 7 | $3,749 | 2020 |
| ARRAY BIOPHARMA INC | 1 | $3,067 | 2020 |
| Edwards Lifesciences Corporation | 2 | $1,400 | 2020 |
| Merck Sharp & Dohme LLC | 13 | $811 | 2020 |
| Janssen Pharmaceuticals, Inc | 1 | $700 | 2020 |
| Terumo Medical Corporation | 1 | $475 | 2020 |
| Siemens Medical Solutions USA, Inc. | 2 | $448 | 2020 |
| Masimo Corporation | 1 | $42 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 94 | $181,369 |
| Gift | 1 | $32,733 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 5 | $23,462 |
| Space rental or facility fees (teaching hospital only) | 3 | $2,100 |
| Charitable Contribution | 2 | $448 |
| Education | 1 | $42 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $73 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-31 | Masimo Corporation | $42 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-23 | Medtronic MiniMed, Inc. | $4,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2020 | |
| 2020-12-17 | CSL Behring | $164 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-12-15 | CSL Behring | $1,539 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-12-15 | Abbott Laboratories | $250 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-12-07 | Boston Scientific Corporation | $4,888 | Research payment | Cash or cash equivalent | WATCHMAN Device, STRUCTURAL HEART | OPTION | 2020 |
| 2020-12-07 | Boston Scientific Corporation | $3,564 | Research payment | Cash or cash equivalent | WATCHMAN Device, STRUCTURAL HEART | OPTION | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-24 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-11-21 | Amgen Inc. | $500 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC. | 2020 |
| 2020-11-18 | PRINCIPIA BIOPHARMA INC. | $1,500 | Research payment | Cash or cash equivalent | A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP) | 2020 | |
| 2020-11-12 | CSL Behring | $3,401 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-11-11 | Abbott Laboratories | $8,568 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-11-10 | CSL Behring | $750 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-11-02 | Boston Scientific Corporation | $1,279 | Research payment | Cash or cash equivalent | WATCHMAN Device, STRUCTURAL HEART | OPTION | 2020 |
| 2020-11-02 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | WATCHMAN Device, STRUCTURAL HEART | OPTION | 2020 |
| 2020-10-27 | CSL Behring | $185 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-10-22 | Edwards Lifesciences Corporation | $700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | 2020 | |
| 2020-10-15 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-15 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-10-06 | CSL Behring | $3,960 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-10-05 | Boston Scientific Corporation | $2,832 | Research payment | Cash or cash equivalent | WATCHMAN Device, STRUCTURAL HEART | OPTION | 2020 |
| 2020-10-05 | Boston Scientific Corporation | $594 | Research payment | Cash or cash equivalent | WATCHMAN Device, STRUCTURAL HEART | OPTION | 2020 |
| 2020-10-05 | Boston Scientific Corporation | $594 | Research payment | Cash or cash equivalent | WATCHMAN Device, STRUCTURAL HEART | OPTION | 2020 |
| 2020-10-05 | Boston Scientific Corporation | $200 | Research payment | Cash or cash equivalent | WATCHMAN Device, STRUCTURAL HEART | OPTION | 2020 |
| 2020-09-27 | Smith+Nephew, Inc. | $32,733 | Gift | In-kind items and services | GENESIS II Device, Recon Knees | 2020 | |
| 2020-09-24 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2020 |
| 2020-09-10 | CSL Behring | $282 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-09-08 | Boston Scientific Corporation | $2,603 | Research payment | Cash or cash equivalent | WATCHMAN Device, STRUCTURAL HEART | OPTION | 2020 |
| 2020-08-20 | Abbott Laboratories | $250 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-08-19 | Abbott Laboratories | $336 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-08-17 | Boston Scientific Corporation | $7,000 | Research payment | Cash or cash equivalent | WATCHMAN Device, STRUCTURAL HEART | OPTION | 2020 |
| 2020-08-17 | Boston Scientific Corporation | $887 | Research payment | Cash or cash equivalent | WATCHMAN Device, STRUCTURAL HEART | OPTION | 2020 |
| 2020-08-13 | Siemens Medical Solutions USA, Inc. | $375 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-08-12 | Abbott Laboratories | $5,645 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-08-05 | PRINCIPIA BIOPHARMA INC. | $1,506 | Research payment | Cash or cash equivalent | A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP) | 2020 | |
| 2020-07-29 | Abbott Laboratories | $398 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2020 |
| 2020-07-23 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-07-23 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-07-16 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-07-16 | Abbott Laboratories | $500 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2020 |
| 2020-07-09 | CSL Behring | $1,613 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-07-08 | Medtronic MiniMed, Inc. | $1,450 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2020 | |
| 2020-07-02 | PRINCIPIA BIOPHARMA INC. | $997 | Research payment | Cash or cash equivalent | A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP) | 2020 | |
| 2020-06-25 | CSL Behring | $206 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-06-24 | Medtronic MiniMed, Inc. | $3,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2020 | |
| 2020-06-16 | Abbott Laboratories | $3,725 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-06-11 | Daiichi Sankyo Inc. | $500 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-06-04 | CSL Behring | $1,613 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-06-02 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-06-02 | CSL Behring | $750 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-05-27 | PRINCIPIA BIOPHARMA INC. | $30,695 | Research payment | Cash or cash equivalent | A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP) | 2020 | |
| 2020-05-20 | Amgen Inc. | $1,212 | Research payment | Cash or cash equivalent | GALACTIC - HF | 2020 | |
| 2020-05-19 | ARRAY BIOPHARMA INC | $3,067 | Research payment | Cash or cash equivalent | A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 IN PATIENTS WITH SYMPTOMATIC GENETIC DILATED CA | 2020 | |
| 2020-05-12 | PRINCIPIA BIOPHARMA INC. | $7,000 | Research payment | Cash or cash equivalent | A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP) | 2020 | |
| 2020-05-12 | PRINCIPIA BIOPHARMA INC. | $1,500 | Research payment | Cash or cash equivalent | A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP) | 2020 | |
| 2020-05-12 | PRINCIPIA BIOPHARMA INC. | $198 | Research payment | Cash or cash equivalent | A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP) | 2020 | |
| 2020-05-12 | PRINCIPIA BIOPHARMA INC. | $71 | Research payment | Cash or cash equivalent | A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP) | 2020 | |
| 2020-05-07 | Merck Sharp & Dohme LLC | $60 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-05-07 | Merck Sharp & Dohme LLC | $30 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
| 2020-05-06 | Abbott Laboratories | $3,867 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-04-29 | Abbott Laboratories | $2,529 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-04-24 | Abbott Laboratories | $400 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-04-22 | Abbott Laboratories | $1,544 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2020 |
| 2020-04-16 | Daiichi Sankyo Inc. | $750 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-04-16 | Daiichi Sankyo Inc. | $750 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-04-09 | CSL Behring | $1,501 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-04-09 | Terumo Medical Corporation | $475 | Research payment | Cash or cash equivalent | Cross-Seal IDE | 2020 | |
| 2020-03-26 | CSL Behring | $315 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-03-23 | Medtronic MiniMed, Inc. | $3,362 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Minimed 670G System Device, Durable Pump | 2020 | |
| 2020-03-17 | CSL Behring | $1,250 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-03-17 | Daiichi Sankyo Inc. | $475 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-03-16 | Amgen Inc. | $175 | Research payment | In-kind items and services | GALACTIC - HF | 2020 | |
| 2020-03-13 | Abbott Laboratories | $11,200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-03-12 | CSL Behring | $564 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-03-05 | Abbott Laboratories | $594 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-02-27 | Abbott Laboratories | $315 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-02-21 | Amgen Inc. | $1,500 | Research payment | Cash or cash equivalent | Kyprolis Drug, Oncology | Modified Kd56 Regimen in US Community Centers | 2020 |
| 2020-02-19 | Abbott Laboratories | $13,971 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-02-15 | Daiichi Sankyo Inc. | $750 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-02-14 | Edwards Lifesciences Corporation | $700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Edwards SAPIEN 3 Transcatheter Heart Valve Device, Transcatheter Heart Valves | 2020 | |
| 2020-02-13 | CSL Behring | $3,192 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-02-12 | Abbott Laboratories | $2,422 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-02-06 | Abbott Laboratories | $750 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-01-30 | Amgen Inc. | $2,693 | Research payment | Cash or cash equivalent | GALACTIC - HF | 2020 | |
| 2020-01-30 | Abbott Laboratories | $250 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-01-30 | Abbott Laboratories | $130 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-01-30 | Abbott Laboratories | $130 | Research payment | Cash or cash equivalent | CardioMEMS HF System Device, Cardiac Arrhythmias and Heart Failure | Hemodynamic-GUIDEd Management of Heart Failure | 2020 |
| 2020-01-29 | Amgen Inc. | $16,050 | Research payment | Cash or cash equivalent | Neulasta Biological, Oncology | Prospective Observational Study of Onpro vs SOC. | 2020 |
| 2020-01-29 | Abbott Laboratories | $1,353 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | SJM Brady MRI Post Approval Study | 2020 |
| 2020-01-29 | Janssen Pharmaceuticals, Inc | $700 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | 2020 | |
| 2020-01-28 | CSL Behring | $131 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-01-17 | Abbott Laboratories | $2,775 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-01-17 | Abbott Laboratories | $800 | Research payment | Cash or cash equivalent | Xience Sierra Coronary Stent System Device, Vascular | XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients | 2020 |
| 2020-01-16 | Abbott Laboratories | $2,000 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MultiPoint Pacing Post Market Study | 2020 |
| 2020-01-11 | Daiichi Sankyo Inc. | $262 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-01-11 | Daiichi Sankyo Inc. | $262 | Research payment | Cash or cash equivalent | Savaysa Drug, Thrombosis | ENVISAGE | 2020 |
| 2020-01-09 | CSL Behring | $4,122 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-01-09 | Abbott Laboratories | $594 | Research payment | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | MOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP) | 2020 |
| 2020-01-09 | Amgen Inc. | $83 | Research payment | In-kind items and services | GALACTIC - HF | 2020 | |
| 2020-01-09 | Merck Sharp & Dohme LLC | $41 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Midland, MI, county Midland County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Midland, MI | County Midland County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 42,724 | 83,757 | 10,077,761 |
| Population, 2020 census P1 | 42,547 | 83,494 | 10,077,331 |
| Median age B01002 | 39.3 | 41.8 | 40.2 |
| Under 18 B01001 | 21.2% | 20.9% | 21.2% |
| 65 and over B01001 | 20.4% | 20.2% | 18.6% |
| Households B11001 | 18,535 | 34,993 | 4,076,369 |
| Foreign born B05002 | 4.8% | 3.2% | 7.2% |
| Median household income B19013 | $73,325 | $77,705 | $72,875 |
| Median family income B19113 | $103,505 | $100,943 | $93,357 |
| Per capita income B19301 | $44,053 | $43,622 | $40,735 |
| Poverty rate B17001 | 10.3% | 10.7% | 13.2% |
| Unemployment rate B23025 | 4.1% | 4.4% | 5.7% |
| Civilian labor force B23025 | 20,510 | 40,590 | 5,018,449 |
| Mean commute (minutes) B08013 | 20.0 | 23.7 | 24.2 |
| Bachelor's degree or higher B15003 | 44.6% | 36.6% | 32.4% |
| Housing units B25001 | 19,459 | 37,160 | 4,622,236 |
| Owner-occupied B25003 | 67.1% | 78.1% | 73.2% |
| Renters B25003 | 32.9% | 21.9% | 26.8% |
| Median home value B25077 | $203,900 | $195,400 | $231,600 |
| Median gross rent B25064 | $1,048 | $1,016 | $1,129 |
| White, not Hispanic B03002 | 86.3% | 89.2% | 72.4% |
| Black B03002 | 2.0% | 1.2% | 13.1% |
| Hispanic or Latino B03002 | 4.6% | 3.4% | 5.9% |
| Asian B03002 | 3.3% | 2.2% | 3.4% |
| American Indian and Alaska Native B03002 | 0.0% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Midland, MI.
Comments